Frova (Frovatriptan Succinate) - Summary

FROVA SUMMARY

FROVA^®
(frovatriptan succinate) Tablets

FROVA (frovatriptan succinate) tablets contain frovatriptan succinate, a selective 5-hydroxy-tryptamine₁ (5-HT_1B/1D) receptor subtype agonist, as the active ingredient.

FROVA is indicated for the acute treatment of migraine attacks with or without aura in adults.

FROVA is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). The safety and effectiveness of FROVA have not been established for cluster headache, which is present in an older, predominately male, population.

FROVA NEWS HIGHLIGHTS

Published Studies Related to Frova (Frovatriptan)

Frovatriptan for the acute treatment of migraine and prevention of predictable menstrual migraine. [2008.05]

Oral contraceptive-induced menstrual migraine. Clinical aspects and response to frovatriptan. [2008.05]

Evaluation of clinical effectiveness of the Frova single-use tracheal tube introducer. [2008.02]

Frovatriptan review. [2007.12]

Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine. [2007.10]

more>>

Clinical Trials Related to Frova (Frovatriptan)

Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals [Recruiting]

A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual Migraine [Completed]

A Randomized Trial of Frovatriptan for the Intermittent Prevention of Menstrual Migraine [Completed]

A Research Study To Evaluate If Frovatriptan Is Safe And Effective In Preventing Migraine Headache After Fasting [Recruiting]

more>>